| abstract |
The present invention relates to chemically modified RNAi constructs for reducing the expression of target genes. Specifically, the invention relates to specific patterns of modified nucleotides that are incorporated into RNAi constructs to improve in vivo stability and efficacy. Also described are methods of inhibiting target gene expression in vivo by administering a pharmaceutical composition comprising a chemically modified RNAi construct and, for example, to treat or ameliorate various medical conditions by administering the chemically modified RNAi construct. To. |